Seres Therapeutics (MCRB) Misses Q2 EPS by 24c
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.70), $0.24 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.2 million.
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vera Bradley (VRA) Tops Q3 EPS by 1c; Offers Light Q4 Outlook; Enters New Licensing Agreements
- PriceSmart (PSMT) Comps Fell 0.2% in November 2016
- Applied DNA Sciences (APDN) Misses Q4 EPS by 1c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!